Protein sequencing

Quantum-Si Announces Upgrades to Analysis Software that will Provide Customers with Higher Data Output and Precision and Shorter Processing Time

Retrieved on: 
Tuesday, April 30, 2024
Other Health, Software, Research, Pharmaceutical, Hardware, Oncology, Data Management, Technology, Science, Biotechnology, Other Science, Health, Proteomics, Intelligence, Senior, New product development, Database, Protein sequencing, NGPS

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced upgrades to its Platinum® Analysis Software to reduce processing time and increase output and precision of Next-Generation Protein Sequencing™ (NGPS) data from the Platinum® instrument.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced upgrades to its Platinum® Analysis Software to reduce processing time and increase output and precision of Next-Generation Protein Sequencing™ (NGPS) data from the Platinum® instrument.
  • “A core component of our Platinum Analysis Software is a database of predicted kinetic signatures that today, contains nearly two million parameters and is generated by our proprietary kinetic model,” said John Vieceli, Senior Vice President of Product Development at Quantum-Si.
  • “Leveraging artificial intelligence and generated sequencing data, we are able to continuously train our model and improve the accuracy of the database, resulting in higher data output and precision.”
    Innovations in this release of the Platinum Analysis Software will provide customers with an average of:
    “Innovations to our Platinum Analysis Software represent a significant opportunity to unlock even deeper insights from our Next-Generation Protein Sequencing technology further building upon the improvements we continue to deliver to the sequencing chemistry,” said Jeff Hawkins, President and CEO of Quantum-Si.
  • “The Platinum Analysis Software enhancements we are launching today represent another significant leap forward in our commitment to continuously provide customers with innovations that deliver tangible value to their proteomics research.”

Quantum-Si to Report First Quarter 2024 Financial Results on May 9, 2024

Retrieved on: 
Thursday, April 18, 2024
Science, Biotechnology, Research, Pharmaceutical, Hardware, Oncology, Health, Technology, PIN, Protein sequencing

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will report financial results for the first quarter 2024 on Thursday, May 9, 2024.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will report financial results for the first quarter 2024 on Thursday, May 9, 2024.
  • Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET.
  • Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call.
  • An archived webcast of the event will be available for replay following the event.

Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Semiconductor, Other Science, Research, Science, Hardware, Genomics, Growth, SVP, University, Software, Cisco, Proteomics, MBA, Pepperdine University, Protein sequencing, Multimedia, Management

Prior to Illumina, Ms. Dowdy spent over 20 years at Cisco Systems, Inc., and held various positions in products, services, and software in the United States, and globally.

Key Points: 
  • Prior to Illumina, Ms. Dowdy spent over 20 years at Cisco Systems, Inc., and held various positions in products, services, and software in the United States, and globally.
  • “We are thrilled to welcome Paula to our Board of Directors,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si.
  • “I am honored to join the Quantum-Si Board of Directors during this pivotal moment in the Company’s journey,” said Ms. Dowdy.
  • Her appointment to the Quantum-Si Board of Directors is effective as of today.

Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencing™ on Platinum® at US HUPO Conference

Retrieved on: 
Thursday, March 7, 2024
Research, Technology, Other Health, Biotechnology, Hardware, Pharmaceutical, Health, Science, Oncology, Other Science, Molecule, Breakfast, PTM, Booth, Protein sequencing, Conference, Doctor of Philosophy, Protein, Johns Hopkins University, Mass spectrometry, Proteomics, Proteome, Assistant professor, Body modification, Hyatt Regency Portland, Microscope

WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.

Key Points: 
  • WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.
  • Additionally, researchers will present data from Platinum and highlight how protein sequencing on the benchtop instrument is providing deeper insights into proteins through streamlined workflows.
  • WHY: Quantum-Si brings the groundbreaking power of single-molecule proteomics with the first-to-market Next-Generation Protein Sequencer™, the Platinum instrument, to every lab, everywhere.
  • WHERE: The 2024 US HUPO Conference is being held at the Hyatt Regency Portland, 375 NE Holladay St, Portland, OR 97232

Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024
Research, Technology, Other Health, Biotechnology, Hardware, Pharmaceutical, Health, Science, Oncology, Other Science, Investment, Growth, Protein sequencing, Acceleration

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • “We are pleased with our ability to launch the version 2 sequencing kit well within the previously provided timeline.
  • We have also released full year 2024 financial guidance.”
    During the fourth quarter of 2023, the Company continued its controlled commercial launch of its Platinum instrument, recording revenue of $400,000.
  • As of December 31, 2023, the Company’s cash and cash equivalents and investments in marketable securities were $257.7 million.

Quantum-Si to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Retrieved on: 
Friday, February 9, 2024
Semiconductor, Health, Technology, Health Technology, Research, Science, PIN, Protein sequencing

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024.
  • Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET.
  • Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call.
  • An archived webcast of the event will be available for replay following the event.

Quantum-Si Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing™ Platform

Retrieved on: 
Monday, February 5, 2024
Science, Software, Other Science, Research, Health, Technology, Genetics, Semiconductor, Proteomics, Protein sequencing, Proteome, Protein, Fine chemical

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the launch of new platform enhancements for Platinum®, with the release of its new V2 Sequencing Kits.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the launch of new platform enhancements for Platinum®, with the release of its new V2 Sequencing Kits.
  • The recent launch marks an expansion of the Company's current Platinum applications, now incorporating peptide barcodes and accommodating new sample types.
  • “With this launch, Quantum-Si is set to deliver unparalleled insights into protein characterization and function, catering to the evolving needs of our diverse customer base.
  • In tandem with its recent announcement, the company’s CEO and executive team have released a video outlining recent enhancements.

Quantum-Si Introduces World’s First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

Retrieved on: 
Thursday, January 18, 2024
Health, Health Technology, Genetics, Other Health, General Health, Clinical Trials, Biotechnology, Platinum, Quantum, History, Protein sequencing, Microscope

TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si’s next-generation protein sequencer™ and associated consumables throughout Japan.

Key Points: 
  • TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si’s next-generation protein sequencer™ and associated consumables throughout Japan.
  • “Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences.
  • We’re poised to empower Japanese researchers with cutting edge technology, fostering unparalleled discoveries,” said Kenjiro Tominaga, Owner, President and CEO of TOMY Digital Biology.
  • We believe that through TOMY's exceptional distribution capabilities and our groundbreaking technology, we will empower researchers in Japan to achieve new milestones in their scientific endeavors."

Quantum-Si Expands Global Reach with Addition of New Distributor

Retrieved on: 
Tuesday, December 12, 2023
Software, Research, General Health, Pharmaceutical, Technology, Semiconductor, Genetics, Health Technology, Science, Biotechnology, Other Science, Health, ELTA, Quantum, Czech Republic, Protein sequencing, Proteomics, Platinum

3Genes Distribution a.s., a prominent technology provider specializing in life science and diagnostics in Eastern Europe will distribute Quantum-Si’s Platinum across the Czech Republic, Slovakia, and Hungary.

Key Points: 
  • 3Genes Distribution a.s., a prominent technology provider specializing in life science and diagnostics in Eastern Europe will distribute Quantum-Si’s Platinum across the Czech Republic, Slovakia, and Hungary.
  • "We are thrilled to welcome this esteemed distributor to our global network, enabling scientists worldwide to harness the power of Platinum and drive groundbreaking discoveries."
  • This strategic agreement marks another milestone in Quantum-Si's efforts to unleash the power of proteomics in every lab, everywhere.
  • It follows closely on the heels of the company’s recently announced agreement with ELTA 90, a Bulgarian distributor to distribute Platinum in Southeast Europe.

Quantum-Si Adds Distributor ELTA 90 as Demand for Platinum™ Grows

Retrieved on: 
Wednesday, November 15, 2023
Technology, Semiconductor, Genetics, Health Technology, Software, Other Health, Biotechnology, General Health, Pharmaceutical, Health, ELTA, Elta, Protein sequencing, Protein, Partnership, Proteomics, Science, Platinum

This agreement between Quantum-Si and ELTA 90 holds immense promise for accelerating scientific research by delivering the game changing tool, Platinum, which interrogates proteins with single-molecule amino acid resolution.

Key Points: 
  • This agreement between Quantum-Si and ELTA 90 holds immense promise for accelerating scientific research by delivering the game changing tool, Platinum, which interrogates proteins with single-molecule amino acid resolution.
  • “We are thrilled to partner with ELTA 90 in this venture.
  • The synergy between Quantum-Si and ELTA 90 represents a major stride toward expanding the field of proteomics,” explained Quantum-Si Chief Executive Officer Jeff Hawkins.
  • We look forward to working with Quantum-Si to unleash the power of next-generation protein sequencing™ in labs throughout Southeast Europe,” expressed Theodor Zamfirov, M.D., Chief Executive Officer of ELTA 90.